Drug Master File Submissions – An Overview
By Naitry Shah, EAS Intern (This article summarizes a White Paper on DMF submissions prepared by EAS Independent Consultant Albert Yehaskel.) Drug Master Files (DMFs) are detailed submissions to the Food and Drug Administration (FDA) that may be used to provide...How to Successfully Respond to FDA 483s and Warning Letters
EAS Senior Advisor for Quality and Compliance, Mr. Robert Fish, will present a webinar on How to Respond to FDA 483s and Warning Letters. He will discuss the correct and incorrect way to prepare these responses with emphasis on the FDA’s expectations. He will also explain why companies may receive an FDA 483 and how to respond in a way to prevent the issuance of a Warning Letter.”
New Drug Development in the 21st Century
By Nancy Chew Most people who work in the pharmaceutical industry know that drug development comprises of pharmaceutical development, animal pharmacology and toxicology studies, and clinical research; many also know that there are quality standards applied to...Managing FDA Inspections
With FDA inspections becoming more frequent, particularly in the dietary supplement world, it is imperative that companies familiarize themselves with how to host and manage such an inspection. We say “manage an FDA inspection” because the more knowledge a company has the better able it will be to make the inspection process move smoothly in the direction that you help set. To provide you with that knowledge, this webinar will cover: